ICLUSIG — Total revenues
Incyte ICLUSIG — Total revenues increased by 3.6% to $35.46M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.0%, from $29.54M to $35.46M. Over 4 years (FY 2021 to FY 2025), ICLUSIG — Total revenues shows an upward trend with a 5.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market penetration, successful clinical adoption, or expanded indications for the drug, while a decrease may signal increased competition, patent expiration, or loss of market share.
Detailed definition
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product, in this cas...
Peer comparison
Comparable to product-specific revenue lines reported by other biopharmaceutical companies, often categorized under oncology or specialty medicine segments.
incy_segment_iclusig_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $28.19M | $28.52M | $27.04M | $26.07M | $26.22M | $25.93M | $27.62M | $27.69M | $29.09M | $27.72M | $27.13M | $30.34M | $26.86M | $29.75M | $27.37M | $29.54M | $32.73M | $37.58M | $34.22M | $35.46M |
| QoQ Change | — | +1.2% | -5.2% | -3.6% | +0.6% | -1.1% | +6.5% | +0.2% | +5.1% | -4.7% | -2.1% | +11.8% | -11.5% | +10.7% | -8.0% | +7.9% | +10.8% | +14.8% | -9.0% | +3.6% |
| YoY Change | — | — | — | — | -7.0% | -9.1% | +2.1% | +6.2% | +10.9% | +6.9% | -1.8% | +9.6% | -7.6% | +7.3% | +0.9% | -2.6% | +21.8% | +26.3% | +25.0% | +20.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's iclusig — total revenues?
- Incyte (INCY) reported iclusig — total revenues of $35.46M in Q1 2026.
- How has Incyte's iclusig — total revenues changed year-over-year?
- Incyte's iclusig — total revenues increased by 20.0% year-over-year, from $29.54M to $35.46M.
- What is the long-term trend for Incyte's iclusig — total revenues?
- Over 4 years (2021 to 2025), Incyte's iclusig — total revenues has grown at a 5.2% compound annual growth rate (CAGR), from $109.40M to $134.07M.
- What does iclusig — total revenues mean?
- The total sales revenue generated by a specific pharmaceutical product.